Astrazeneca Share Discussion Threads

[jimarilo] 04/11/2022 13:29

DIED SUDDENLY | OFFICIAL TRAILER - Streaming November 21st




Dr. Mike Yeadon — Former Pfzer VP names names of his ex-#BigPharma colleagues

& calls for accountability for those directly responsible for #CrimesAgainstHumanity

[aidenabettin] 03/11/2022 04:35

Nothing to do with vaccines?.Not even a possibilty?. hTTps://www.bbc.co.uk/news/health-63486547

[jimarilo] 02/11/2022 08:27

THE AstraZeneca Covid-19 vaccine has all but disappeared from use. We need to know why, and whether troubling evidence from its trials was ignored by the regulators or withheld from the public. That is why HART, the independent Health Advisory and Recovery Team, has demanded a ‘Pfizer files’ style data release from the Medicines and Healthcare Product Regulatory Agency (MHRA).

Last week, we submitted an FoI request to the MHRA prepared by PJH Law requiring the release of all data submitted by AstraZeneca in their application for a licence for their Covid-19 vaccine (AZD1222/Vaxzevria), the data that the MHRA relied on before granting a conditional marketing authorisation for its use.

[1knocker] 26/10/2022 11:37

Growthpotential, do you know what the dividend payment was? A tad less than 17.9p per share I think you will find .....

[aidenabettin] 24/10/2022 11:09

hTTps://themadtruther.com/2022/10/21/uk-documentary-exposes-lies-behind-safe-and-effec

[growthpotential] 20/10/2022 10:01

And you missed the dividend payment

[1knocker] 13/10/2022 15:54

I sold a large chunk of my holding in late August at 114.5, and my repurchase limit order has just triggered at 96.6. It gets the capital committed down a bit on what has been a core holding for me for years, but in this market any purchase leaves one wondering if it might have been wiser to wait a bit longer!

[johnwise] 12/10/2022 21:09

VIDEO

Viral transmission not tested in Pfizer trials

[jimarilo] 12/10/2022 18:23

20 million deaths and 2 billion adverse events estimated from the jabs world wide .........so far !!




Steve73 12 Oct '22 - 03:32 - 140076 of 140098

ref. the adverse reactions & deaths from the jabs.


"Our world in data" indicates that 68.2% of the global pop'n has had at least one vax (that's c. 5.5 Bn souls). It also indicates 12.8 Bn doses have been administered, which means the average number of shots per person is c. 2.3.

Assuming the estimated 2.2Bn adverse reactions is even close to correct, that's 40% of everyone jabbed. (of course, some people could have had more than one adverse reaction, so the number/% of people having adverse reactions is almost certainly much less than this.

The 20 Mn deaths represents around 0.37% (this represent the true number/% since people can only die once.!!). Worldometers website suggests Covid itself has caused only 6.5 Mn deaths (mostly among the elderly/co-morbid of course).

So it appears that the jab have caused mor than three times as many as died from covid itself.... and that's just so far. Many people jabbed are likely to die prematurely.

Going back to the "our world in data"..
84% of high income countries have been jabbed,
80% of upper middle income,
64% of lower middle income,
but just 23% of lower income countries.

If this doesn't tell you that the upper/middle income countries have been directly targeted for depopulation... and these are the sections of the population that consume "most" of the worlds energy/oil/resources.

Clearly, the low income populations are being preserved to "serve" the elite after the Great Reset has been completed.

links I've used:

[jimarilo] 12/10/2022 18:21

See this: Private business jets demanding unvaccinated pilots

[mirandaj] 08/10/2022 07:19

Interesting comments if interested on AstraZeneca FYI:

[blackhorse23] 07/10/2022 09:08

bought RENE (LSE) today

[1knocker] 06/10/2022 18:41

If there is a market fall AstraZ will fall along with everything else. I sold 20% of my holding at 114 ( I now wish I had been more decisive and sold more) and await a further dip before buying back in. The bond markets show how stressed the markets are. The odds look pretty strong on further falls to provide an opportunity to buy back before the month is out. I have a limit order in. I am happy to wait on the sidelines with cash in hand.

This has been a depressing year for investors, but it has at least provided numerous opportunities to reduce the capital committed to core holdings while maintaining or even increasing the number of shares held, and with shares paying dividends half yearly there is not even much risk of dropping a dividend.

[lostabillion] 04/10/2022 07:10

AZN eyeing up Avacta!?!

[bostonborn] 02/10/2022 18:53

thanks for that; rech

[rech] 02/10/2022 11:33

@ bostonborn

In Questor’s view, investors do not necessarily face a binary choice between safety and growth. Indeed, some companies, such as the FTSE 100 pharmaceutical company AstraZeneca, offer the best of both.

From a defensive standpoint, its recent half-year results highlight its financial strength amid an uncertain global economic outlook. Revenue and core profits grew by 48pc and 44pc respectively and all business units delivered an improved performance.

This led the company to raise its sales guidance for the full year: it now expects a percentage increase in the low 20s. A net‑debt‑;to‑equity ratio of 69pc further highlights its capacity to withstand the sharp monetary policy tightening that is taking place across the developed world.

The company’s improving financial performance allows it to invest greater sums in research and development. Core R&D spending in the first half of the year increased by 40pc and as a proportion of sales it is now 1 percentage point higher at 23pc than in the same period of the previous year. This should strengthen its product pipeline in an era when rising healthcare spending creates significant long-term growth opportunities.

The world’s population is rapidly growing and quickly ageing. Between now and 2050 the UN forecasts it to grow from eight billion people to 9.7 billion people.

Over the same period the number of people aged 65 or over is expected to almost double to 1.6 billion. With 71pc of worldwide deaths caused by non-communicable diseases such as cancer, cardiovascular disease and others that cannot be transmitted between people, demand for AstraZeneca’s oncology and biopharmaceutical products is likely to rise.

Last year’s acquisition of rare diseases specialist Alexion provides a further long-term growth opportunity. Currently, 400 million people are affected by a rare disease but only 5pc of the more than 7,000 rare diseases known to exist today have treatments.


Separately, AstraZeneca’s large presence in emerging markets, which account for 28pc of its revenues, makes it well placed to capitalise on their growth potential. In fact, according to the IMF they will grow almost three times faster than developed markets next year.

Of course, AstraZeneca is not immune from potential threats to its performance. Rumours persist that its chief executive, Pascal Soriot, is to leave in the near future. His eventual departure, after he led the company to a vast improvement in fortunes since he took over a decade ago, is almost certain to cause a degree of uncertainty, which is likely to be reflected in heightened share price volatility.

Similarly, the company’s outperformance of the wider stock market means it trades on a relatively rich valuation. It has gained 35pc and beaten the FTSE 100 by 41 percentage points since this column first advised readers to buy the stock in August 2019. As a result it now trades at around 17 times forecast earnings.

In Questor’s view, AstraZeneca is extremely worthy of its premium valuation. Its potent mix of defensive and growth characteristics is particularly attractive in the current economic environment.

Its exposure to emerging markets, its focus on non-communicable diseases that are likely to become more prevalent and its growing R&D spending mean it should remain a mainstay of investors’ portfolios. Buy

[bostonborn] 02/10/2022 11:03

Today's Questor in the telegraph has AZN as a buy. Can someone please post the complete article.
It was tipped in the Times on Thursday or Friday. It may be a 'repeat' of this article. Summary of which was 'great pipeline of new drugs coming through over the next year or two, which should bring growth; also a 'safe' share'

[sb34] 26/9/2022 21:46

AZN Plc share going to match £115 price anytime soon over the next few weeks ??

[evianone] 26/9/2022 15:55

Danger is our best uk companies look cheap and will be taken over :-(

[montyhedge] 26/9/2022 08:15

Weak pound certainly boosting profits of FTSE 100 dollar earners.

[philanderer] 19/9/2022 18:53

Investors wiped more than $10bn off the market value of the main Covid-19 vaccine makers on Monday after US president Joe Biden said “the pandemic is over”.

Shares in Moderna, BioNTech and Novavax fell as much as 9 per cent